PREHISTIN SHOWS POSITIVE RESULTS IN ALLERGY TREATMENT

Cobalis, a pharmaceutical biotech company specializing in the development of anti-allergy medications, announced that preliminary analyses performed on data collected during their first Phase III trial for its flagship anti-allergy medication PreHistin has demonstrated that pre-seasonal treatment with the drug reduces allergy symptoms.

The Phase III study was conducted using a total of 715 patients, aged 17 to 75, with a demonstrated multiyear history of sensitivity to Mountain Cedar pollen. The patients were randomized into four study arms, and 641 patients completed the study.

Patients received either placebo or active study drug during a six week trial. Participants were dosed for three weeks were administered prior to the onset of the allergy season, and were then studied for an additional three weeks following the onset of the allergy season. Patients in two of the study arms received the active medication prior to the onset of the allergy season, and patients in the other two arms received only placebo during this period.